Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 21,536 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 21,536 shares of Phibro Animal Health stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $45.23, for a total value of $974,073.28. Following the completion of the sale, the chief executive officer owned 14,041 shares in the company, valued at $635,074.43. This represents a 60.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Thursday, November 13th, Jack Bendheim sold 8,801 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.47, for a total value of $391,380.47.
• On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.29, for a total transaction of $1,734,742.87.
• On Friday, November 7th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $42.86, for a total value of $150,867.20.
• On Tuesday, November 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.10, for a total value of $151,712.00.
• On Thursday, October 30th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.07, for a total value of $144,566.40.
• On Tuesday, October 28th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.56, for a total value of $146,291.20.
• On Thursday, October 23rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.18, for a total transaction of $141,433.60.
• On Wednesday, October 22nd, Jack Bendheim sold 11,859 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.27, for a total transaction of $477,561.93.
• On Monday, October 20th, Jack Bendheim sold 16,075 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.38, for a total transaction of $649,108.50.
• On Friday, October 17th, Jack Bendheim sold 700 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.03, for a total value of $28,021.00.

Phibro Animal Health Stock Performance

Shares of Phibro Animal Health stock opened at $44.70 on Friday. The company has a market cap of $1.81 billion, a PE ratio of 37.88, a P/E/G ratio of 1.24 and a beta of 0.81. The business has a 50-day simple moving average of $40.32 and a 200-day simple moving average of $31.62. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $46.42. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th will be given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, November 26th. Phibro Animal Health’s payout ratio is currently 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Phibro Animal Health by 0.4% in the first quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company’s stock valued at $32,500,000 after buying an additional 6,784 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of Phibro Animal Health by 0.5% during the first quarter. Acadian Asset Management LLC now owns 782,939 shares of the company’s stock valued at $16,713,000 after buying an additional 4,144 shares during the period. Geode Capital Management LLC grew its position in shares of Phibro Animal Health by 1.4% in the second quarter. Geode Capital Management LLC now owns 554,927 shares of the company’s stock valued at $14,175,000 after purchasing an additional 7,841 shares during the period. Nuveen LLC purchased a new stake in shares of Phibro Animal Health during the 1st quarter valued at $10,312,000. Finally, Invesco Ltd. grew its position in Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock valued at $8,282,000 after acquiring an additional 186,087 shares during the period. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PAHC has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Tuesday. JPMorgan Chase & Co. raised their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Bank of America boosted their target price on Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a report on Friday, August 29th. Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday. Finally, Morgan Stanley set a $34.00 price target on Phibro Animal Health in a research report on Thursday, August 28th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Phibro Animal Health currently has an average rating of “Hold” and a consensus target price of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.